TVRD Fundamental Analysis - TVARDI THERAPEUTICS INC

Name: TVARDI THERAPEUTICS INC (TVRD) Stock
Brand: TVARDI THERAPEUTICS INC
Rating: 3 (3 reviews)

Fundamental Rating

Overall TVRD gets a fundamental rating of 2 out of 10. We evaluated TVRD against 191 industry peers in the Pharmaceuticals industry. The financial health of TVRD is average, but there are quite some concerns on its profitability. TVRD has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

TVRD had negative earnings in the past year.

In the past year TVRD has reported a negative cash flow from operations.

In the past 5 years TVRD reported 4 times negative net income.

TVRD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TVRD's Return On Assets of -115.70% is on the low side compared to the rest of the industry. TVRD is outperformed by 80.10% of its industry peers.

		Industry Rank	Sector Rank
ROA	-115.7%
ROE	N/A
ROIC	N/A

ROA(3y)-100.93%

ROA(5y)-67.1%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of TVRD (86.08%) is better than 89.01% of its industry peers.

TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	86.08%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.

TVRD has more shares outstanding than it did 1 year ago.

The number of shares outstanding for TVRD has been increased compared to 5 years ago.

There is no outstanding debt for TVRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -27.87, we must say that TVRD is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -27.87, TVRD is doing worse than 86.39% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-27.87

ROIC/WACCN/A

WACC8.88%

2.3 Liquidity

A Current Ratio of 32.48 indicates that TVRD has no problem at all paying its short term obligations.

The Current ratio of TVRD (32.48) is better than 97.91% of its industry peers.

A Quick Ratio of 31.73 indicates that TVRD has no problem at all paying its short term obligations.

TVRD has a Quick ratio of 31.73. This is amongst the best in the industry. TVRD outperforms 97.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	32.48
Quick Ratio	31.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TVRD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.11%.

Looking at the last year, TVRD shows a very negative growth in Revenue. The Revenue has decreased by -49.96% in the last year.

The Revenue has been growing by 9.21% on average over the past years. This is quite good.

EPS 1Y (TTM)-37.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.49%

Revenue 1Y (TTM)-49.96%

Revenue growth 3Y-46.26%

Revenue growth 5Y9.21%

Sales Q2Q%-100%

3.2 Future

TVRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.25% yearly.

TVRD is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.

EPS Next Y98.33%

EPS Next 2Y39.88%

EPS Next 3Y25.29%

EPS Next 5Y14.25%

Revenue Next Year-82.49%

Revenue Next 2Y-89.11%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.

Also next year TVRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TVRD's earnings are expected to grow with 25.29% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.88%

EPS Next 3Y25.29%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TVRD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (11/14/2025, 8:00:01 PM)

After market: 4.03 0 (0%)

4.03

-0.08 (-1.95%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-12 2025-11-12/amc

Earnings (Next)03-09 2026-03-09/amc

Inst Owners20.85%

Inst Owner Change1.64%

Ins Owners19.12%

Ins Owner Change0%

Market Cap37.80M

Revenue(TTM)20.97M

Net Income(TTM)-45.06M

Analysts77.14

Price Target20.11 (399.01%)

Short Float %22.06%

Short Ratio4.04

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)49.63%

Min Revenue beat(2)-10.63%

Max Revenue beat(2)109.89%

Revenue beat(4)2

Avg Revenue beat(4)34.26%

Min Revenue beat(4)-17.21%

Max Revenue beat(4)109.89%

Revenue beat(8)4

Avg Revenue beat(8)5.44%

Revenue beat(12)7

Avg Revenue beat(12)0.17%

Revenue beat(16)9

Avg Revenue beat(16)-1.11%

PT rev (1m)-65.5%

PT rev (3m)-63.47%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)-20.51%

EPS NY rev (3m)-40.53%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-37.5%

Revenue NY rev (3m)-50%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.99
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-78.48

EYN/A

EPS(NY)-3.39

Fwd EYN/A

FCF(TTM)-3.82

FCFYN/A

OCF(TTM)-3.8

OCFYN/A

SpS0.81

BVpS-0.86

TBVpS-0.86

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-115.7%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	86.08%
FCFM	N/A

ROA(3y)-100.93%

ROA(5y)-67.1%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.19

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	32.48
Quick Ratio	31.73
Altman-Z	-27.87

F-Score6

WACC8.88%

ROIC/WACCN/A

Cap/Depr(3y)492.59%

Cap/Depr(5y)332.09%

Cap/Sales(3y)8.69%

Cap/Sales(5y)5.3%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-37.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.49%

EPS Next Y98.33%

EPS Next 2Y39.88%

EPS Next 3Y25.29%

EPS Next 5Y14.25%

Revenue 1Y (TTM)-49.96%

Revenue growth 3Y-46.26%

Revenue growth 5Y9.21%

Sales Q2Q%-100%

Revenue Next Year-82.49%

Revenue Next 2Y-89.11%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

EBIT growth 1Y76.89%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year25.9%

EBIT Next 3Y10.58%

EBIT Next 5YN/A

FCF growth 1Y59.22%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y59.45%

OCF growth 3YN/A

OCF growth 5YN/A

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the fundamental rating for TVRD stock?

ChartMill assigns a fundamental rating of 2 / 10 to TVRD.

Can you provide the valuation status for TVARDI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to TVARDI THERAPEUTICS INC (TVRD). This can be considered as Overvalued.

How profitable is TVARDI THERAPEUTICS INC (TVRD) stock?

TVARDI THERAPEUTICS INC (TVRD) has a profitability rating of 1 / 10.

What is the earnings growth outlook for TVARDI THERAPEUTICS INC?

The Earnings per Share (EPS) of TVARDI THERAPEUTICS INC (TVRD) is expected to grow by 98.33% in the next year.

TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the fundamental rating for TVRD stock?

Can you provide the valuation status for TVARDI THERAPEUTICS INC?

How profitable is TVARDI THERAPEUTICS INC (TVRD) stock?

What is the earnings growth outlook for TVARDI THERAPEUTICS INC?